BIO-TECHNE Corp vs Materials Select Sector SPDR Fund — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Materials Select Sector SPDR Fund trades at $49.23 (market cap $7.86B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| TECH | XLB | |
|---|---|---|
Market Cap | $11.37B | $7.86B |
Volume | 3,153,511 | 9,786,394 |
Sector | Health | — |
52-Week High | $72.61 | $53.67 |
52-Week Low | $43.31 | $42.23 |
Typical Hold Time | 63 Days | 70 Days |
Enterprise Value | $11.40B | — |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
XLB trades at $48.98, down 1.51% for the day, with a bearish technical signal from moving averages. The materials sector ETF faces headwinds amid September's broader market weakness outside of technology. Recent analysis indicates the portfolio is heavily concentrated in chemicals (49% of assets) with construction materials appearing moderately overvalued. The fund offers low-cost exposure to large-cap U.S. materials companies but faces cyclical pricing pressures.
The materials sector shows potential from infrastructure and manufacturing trends, though much of the cyclical recovery appears priced in. Key risks include sector concentration, economic sensitivity, and competition from China in critical minerals. Analyst sentiment remains cautious with limited near-term upside potential despite long-term infrastructure tailwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →